Glycogen Synthase Kinase-3 Signaling and Therapeutics

Glycogen Synthase Kinase-3 (GSK-3) is a constitutively active serine/threonine kinase with two paralogues, GSK-3α and GSK-3β, that play pivotal roles in regulating metabolism, cell fate decisions, and signal transduction. Initially characterised as a regulator of glycogen synthesis, GSK-3 has since been implicated in diverse pathways including Wnt/β-catenin, PI3K/Akt and Hedgehog signalling, where it phosphorylates substrates to mark them for proteasomal degradation or to modulate their activity. Dysregulation of GSK-3 activity is linked to the pathogenesis of numerous disorders such as Alzheimer’s disease, bipolar affective disorder, diabetes and various malignancies. Small-molecule inhibitors and peptide-based modulators have been developed to target its ATP-binding pocket or to alter its regulatory phosphorylation sites, leading to therapeutic effects in preclinical models of neurodegeneration, cancer and metabolic disease. Emerging work emphasises the context-dependent, bifunctional roles of GSK-3 in promoting cell survival or apoptosis, and highlights the necessity of pathway-selective intervention to avoid off-target consequences. Clinical evaluation of irreversible and competitive inhibitors underscores the promise of long-residence-time compounds, while advances in structure-guided design and isoform selectivity offer a blueprint for next-generation therapeutics. Collectively, the GSK-3 signalling network represents both a cornerstone of fundamental cell biology and a fertile ground for translational discovery across a spectrum of human diseases.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Glycogen Synthase Kinase-3 Signaling and Therapeutics publication trend

The graph below shows the total number of articles in glycogen synthase kinase-3 signaling and therapeutics across all publications each year (not limited to Nature Index journals).

Technical terms

Glycogen Synthase Kinase-3 (GSK-3): A ubiquitously expressed serine/threonine kinase with two isoforms, GSK-3α and GSK-3β, involved in multiple cell-signalling cascades.

β-Catenin: A transcriptional co-activator in the canonical Wnt pathway whose stability is regulated by GSK-3-mediated phosphorylation.

ATP-Competitive Inhibitor: A small molecule that binds the ATP-binding site of a kinase to block its catalytic activity.

Autophagy: A lysosome-dependent process for degrading and recycling cellular components, modulated by GSK-3 in stress responses.

Xenograft Model: An in vivo experimental system in which human cells or tissues are implanted into immunodeficient animals to study disease and therapy.

References

1. Elraglusib (formerly 9-ING-41) possesses potent anti-lymphoma properties which cannot be attributed to GSK3 inhibition. Cell Communication and Signaling (2023).
2. Multifaceted Roles of GSK‐3 in Cancer and Autophagy‐Related Diseases. Oxidative Medicine and Cellular Longevity (2017).
3. GSK-3: Functional Insights from Cell Biology and Animal Models. Frontiers in Molecular Neuroscience (2011).
4. GSK‐3β: A Bifunctional Role in Cell Death Pathways. International Journal of Cell Biology (2012).
5. Small‐Molecule Inhibitors of GSK‐3: Structural Insights and Their Application to Alzheimer′s Disease Models. International Journal of Alzheimer's Disease (2012).
6. Differential Regulation of Glycogen Synthase Kinase 3β by Insulin and Wnt Signaling*. Journal of Biological Chemistry (2000).